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Effective induction therapy for anti-SRP
associated myositis in childhood: A small
case series and review of the literature
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Abstract
Background: Anti-Signal Recognition Particle associated myopathy is a clinically and histopathologically distinct
subgroup of Juvenile Idiopathic Inflammatory Myositis, which is under-recognised in children and fails to respond to
conventional first line therapies. We present three cases where remission was successfully induced using combination
therapy with intensive rehabilitation.
Case presentations: Three new patients are reported. All 3 cases presented with profound, rapid-onset, proximal
myopathy and markedly raised CK, but no rash. Histology revealed a destructive myopathy characterized by scattered
atrophic and necrotic fibres with little or no inflammatory infiltrate. All 3 patients responded to induction with
cyclophosphamide, IVIG and rituximab, in conjunction with intensive physiotherapy and methotrexate as the maintenance
agent. Our patients regained near-normal strength (MMT > 70/80), in contrast with the current literature where >50% of
cases reported severe residual weakness.
A literature search on paediatric anti-SRP myositis was performed to June 2016; PubMed was screened using a combination
of the following terms: signal recognition particle, autoantibodies, antibodies, myositis, muscular diseases, skeletal muscle,
childhood, paediatric, juvenile. Articles in a foreign language were excluded. Nine case studies were found.
Conclusion: This paper supports the hypothesis that anti-SRP myositis is distinct from other JIIM. It is an important
differential to JDM and should be considered where there is severe weakness without rash or if highly elevated muscle
enzymes (CK > 10,000 U/l) are found. Early identification is essential to initiate aggressive medical and physical therapy.
Greater international collaboration and long-term follow-up data is needed to establish the most effective treatment
strategy for this rare group of patients.
Background
Juvenile Idiopathic Inflammatory myopathies (JIIM) are a het-
erogeneous group of autoimmune diseases that were originally
categorized by their clinical phenotypes. In recent years, it has
become clear that there is scope for further sub classification
using serological phenotypes defined by Myositis-Specific
Antibodies (MSA’s) and Myositis-Associated Antibodies
(MAA’s) [1–8]. Anti-Signal Recognition Particle (anti-SRP) is
an MSA which has been well described in the adult
population but rarely in children. JIIM associated with anti-
SRP antibodies has been characterized by severe, progressive
proximal muscle weakness, minimal skin involvement, and
markedly raised CK (usually more than 40 times greater than
the upper limit of normal) with high levels of disability [2].
Thus far, the paediatric literature has demonstrated a
picture consistent with the adult population, however
only a handful of cases have been reported [9–15].
Currently the limited number of cases precludes defini-
tive conclusions to guide clinicians in their management
and thus a variety of therapies have been trialled on an
individual basis, with variable success.
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In this paper, we discuss three new cases of anti-SRP
myositis and relate this to the published literature. Our
report highlights the use of an aggressive induction regime
where standard therapy failed, including combination of
intravenous immunoglobulin (IVIG), cyclophosphamide
and rituximab, with intensive physical therapy, which
resulted in positive outcomes in each case.
Case presentations
Three new cases are reported. All patients were included
following full, informed parental consent and age appro-
priate assent. The study was approved by the North
Yorkshire Multi Centre Research Ethics Committee, Ref:
MREC/1/3/22.
A literature search on paediatric anti-SRP myositis was
performed to June 2016; PubMed was screened using a
combination of the following terms: signal recognition
particle, autoantibodies, antibodies, myositis, muscular
diseases, skeletal muscle, childhood, paediatric and ju-
venile. Articles in a foreign language were excluded.
Nine case studies were found.
Case reports
Case study 1
A previously healthy, 14-year-old female of Afro-Caribbean
descent, born in the UK, presented with a 4 month history
of progressive severe proximal muscle weakness, myalgia,
ankle swelling and headaches. A fortnight prior to these
symptoms she recalled a coryzal illness.
Examination revealed a profound, weakness; with a
MMT8 score of 34/80 and a CMAS score 21/53, in a
proximal distribution. There were no skin signs.
Investigations showed a markedly raised CK of
23,111 U/l (50–240 U/l), LDH of 4553 U/l (380–640 U/
L) and ALT of 300 U/I (10–45 U/l). EMG was compat-
ible with polymyositis and MRI leg revealed widespread
symmetrical signal abnormality. Thigh muscle biopsy
showed destructive necrotising myopathy with minimal
inflammatory infiltrate (Fig. 1). Chest X-ray was normal
but PFT’s revealed a reduced DLCO/VA of 69%. CT
chest, ECG and echocardiogram were normal. Video
fluoroscopy demonstrated moderate oro-pharyngeal dys-
phagia with reduced bulbar musculature.
Initial medical treatment was with high dose pulsed
IVMP, 1 g daily for 3 days, followed by daily 1 mg/kg
prednisolone and weekly subcutaneous methotrexate at
15 mg/m2. An improvement was noted in CK levels but
she remained profoundly weak. In week 4 of admission
she received a further course of IVMP and had her first
dose of rituximab at 750 mg/m2, which was repeated
2 weeks later. Bloods at week 8 confirmed B cell deple-
tion. Towards the end of week 8 the patient developed
fever and respiratory distress and was admitted to the
PICU for 5 days for treatment of CMV pneumonitis and
CPAP support. In week 9, whilst in PICU, she com-
menced IVIG 2 g/kg for treatment of her pneumonitis
as well as her myositis. She continued IVIG 2 g/kg fort-
nightly for 5 doses then monthly dosing. Following
recovery from her respiratory infection Patient 1 had a
steady improvement in her muscle strength which pla-
teau’d at an MMT8 score of 60. MRI scans of her thighs
at week 19 continued to show active disease and muscle
atrophy therefore in week 20 she was commenced on
pulsed intravenous cyclophosphamide at 500 mg/m2,
monthly, for 5 doses. She was discharged at 22 weeks on
methotrexate 25 mg weekly and prednisolone 5 mg daily
with a plan to complete further doses of IVIG and cyclo-
phosphamide as an outpatient. Her MMT8 score at
discharge was 61/80, which increased to 74/80 at
12 months from presentation (Fig. 2a). Her CMAS score
at 12 months was 48/53, by which time she was at
school full-time and able to re-join her physical educa-
tion and dance classes. CK at discharge was 2582 U/l.
Her discharge maintenance treatment was monthly IVIG
2 g/kg, weekly methotrexate 15 mg/kg and 10 mg pred-
nisolone with a plan to wean as per protocol.
Case study 2
A 13-year-old female of Afro-Caribbean descent, pre-
sented with a 4-week history of myalgia, proximal
muscle weakness, limb and peri-orbital swelling and
shortness of breath on exertion. Her symptoms were
preceded by a mild coryzal illness and urticarial rash.
Examination revealed profound, asymmetrical proximal
weakness preventing ambulation with an MMT8 score of
44/80 and CMAS of 31/53. She had Raynaud’s phenom-
ena but no cutaneous features of JDM. Cardiovascular,
respiratory and SLT exam were normal.
CK was elevated at 25,937 U/l (50-240 U/l) with an
AST of 606 IU/l (10–40 U/l) and LDH of 2128 IU/l
(380–640 U/l). Urine was positive for myoglobin but
renal function was preserved. MRI thigh revealed
evidence of myositis and fasciitis and EMG was consist-
ent with a myopathic process. Muscle biopsy showed a
necrotising myositis (Fig. 1). PFT’s revealed a DLCO/VA
ratio 43%. Echo and ECG were normal.
Initial medical treatment was 2 courses of IVMP 1 g daily
for 3 days 10 days apart, followed by oral prednisolone, ini-
tially at 1 mg/kg, and weekly sub-cutaneous methotrexate
at 15 mg/m2. During this time her weakness progressed
with a trough MMT8 of 39/53. In her 3rd week of admis-
sion she had a 750 mg/m2 dose of rituximab, together with
500 mg/m2 cyclophosphamide. She developed a groin ab-
scess and as she had already depleted her B cells, no further
doses of rituximab were given and cyclophosphamide was
temporarily placed on hold. In week 6, she was commenced
on monthly IVIG 2 g/kg and at week 10, she restarted
cyclophosphamide for a total of 5 doses. At 17 weeks, she
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had improved significantly and was discharged on weekly
methotrexate 15 mg/m2, monthly IVIG 2 g/kg and daily
prednisolone 5 mg, to wean as per protocol. Her CK on
discharge was 110 U/l, CMAS score was 31/53. At her 4-
month follow-up, she had returned to school with an
MMT8 score of 78/80 (Fig. 2b).
Case study 3
The third case is an 11-year-old female of West African
descent. She presented with profound proximal myopathy,
myalgia and arthralgia following an upper respiratory tract
infection a week previously. Examination revealed an
extreme proximal weakness scoring 0/53 CMAS and an
un-recordable MMT8. There was no joint restriction or
inflammation and no rash. She described no difficulty in
swallowing but her voice had developed a nasal quality.
CK was elevated at 19,808 U/l (50–240 U/l), AST of
512 IU/l (10–40 U/l), and LDH of 3567 IU/l (380–640 U/
l). MRI of the thighs showed diffuse patchy oedema in all







Fig. 1 Muscle histology of all 3 SRP cases: a-f haematoxylin and eosin (H&E) stain showing scattered necrotic fibres (arrows) and atrophic fibres
(open arrows) across the biopsies. c and f Numerous regenerating fibres (open arrow heads) could also be seen in case 3. g-i there was very little
staining for CD3 in case 1 (arrow) and none in case 2 h. Moderate levels of CD3 were seen in case 3 in the endomysial compartment (i, arrows).
j-l there was diffuse MHC class 1 up regulation in all 3 cases, but case 3 had higher levels at the sarcolemma and within fibres. m-o MAC C5b9
stained necrotic fibres in all cases (arrows) and also some endomysial capillaries (not shown). p-r there was scattered expression of neonatal
myosin in the muscle fibres of case 1 and 2 (p & q, arrows) and expression in numerous fibres in case 3 r. Scale bars: a, b, f, m-o, q and r – 100 μm. c,
g-l, p - 250 μm. d and e - 50 μm
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Muscle biopsy revealed a destructive myopathy (Fig. 1).
CXR was normal but CT thorax showed ground glass
opacification and video fluoroscopy was consistent with
chronic micro-aspiration therefore she received nasogas-
tric feeding and soft diet as an inpatient. Echo was normal.
PFTs showed FEV1 59%, FVC 58% predicted, whilst repeat
CT chest at 4 months was normal. A respiratory consult
suggested that abnormal PFTs represented weakness
rather than interstitial lung disease.
Medical treatment began with 2 courses of pulsed
IVMP 1 g over 3 days, followed by daily oral prednisol-
one, initially at 2 mg/kg, and methotrexate 15 mg/m2.
At week 2 she had her first dose of cyclophosphamide
500 mg/m2, monthly dosing for 5 doses, together with
IVIG at 1 g/kg initially at fortnightly dosing. Her cyclo-
phosphamide dose was decreased to 375 mg/m2 after 2
doses due to microscopic haematuria. Muscle strength
began to improve but regressed again after a period of
reduced access to physiotherapy due to chickenpox con-
tact. Her medical treatment was subsequently escalated
and, at week 16, she received her first dose of rituximab,
750 mg/m2, with a further dose a fortnight later. Follow-
ing this she had a steady improvement and was
discharged after a 19-week admission on prednisolone
15 mg daily and methotrexate 20 mg weekly, with an
MMT8 of 69/80 and CMAS of 49/53 (Fig. 2c). Her CK
at discharge was 269 U/L. Discharge maintenance ther-
apy was weekly methotrexate 15 mg/kg, monthly IVIG
2 g/kg and daily 10 mg prednisolone, with a plan to
reduce steroids as per local protocol.
Approach to physical therapy
All 3 girls in our series commenced intensive physio-
therapy from the day of admission. Initially, as they were
unable to move their limbs with anti-gravity movements,
therapy was centred round stretching muscle length to
regain full joint range of movement, taking to care to
avoid overstretching and hypermobility. Care had to be
taken when our patients had improved enough to walk,
as extreme core muscle and gluteal weakness posed a
significant risk of falls and injury. Reduced head control
was an issue and the girls were provided with reclining
Fig. 2 Summary of treatment and clinical course for Case 1 (a), Case 2 (b) and Case 3 (c). Line chart of muscle strength (dotted line with circles,
Manual muscle testing, MMT, range 0–80, low numbers indicate weakness) and creatine kinase (CK, intermittent line) from diagnosis. Bold arrows
indicate treatment with Rituximab. Duration of treatment is represented by horizontal lines above chart. Short vertical lines indicate treatment
with high dose intravenous methylprednisolone (IVMP). Narrowing of the top horizontal line represents tailing of the oral corticosteroid dose
(PO prednisolone)
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wheelchairs with headrests so they could engage in
activities without muscle fatigue.
Initially the physiotherapy programme consisted of
active-assisted exercises targeting individual muscles and
avoiding complex movements that require multiple mus-
cles working effectively. Recovery of muscle strength was
extremely slow with the proximal muscle groups; neck
flexors, abdominals, gluteals and vastus medialis took 2–
3 months before recovery of functional strength began.
Literature review
The PubMed database was studied up to May 2016.
Nine cases of Anti-SRP myositis in children, aged 16
and under, were identified [9–15]. Eight cases were
female and 1 male. The mean age was between 11 and
12 with the youngest patient aged 6 [9]. Ethnicity was
known for 8/9 patients [9–14]. The majority of cases
were non-Caucasian; 4 were Japanese [9–12] 3 were
African- American [13], one was Alaskan [14]. Chrono-
biological data was collected in half the cases; these
occurred between October- February [13, 14]. Half
reported a preceding infection in the months prior to
onset [11–13].
Severe proximal weakness in the absence of typical
skin findings of JDM was a universal feature. Common
associated symptoms were Raynaud’s (3/8) [13, 15], arth-
ritis (3/8) [13, 14] and dysphagia (3/8) [11–13, 15]. 3
children had signs of restrictive lung disease on PFT’s
[13–15], although as seen in our cases this may reflect
respiratory muscle weakness rather than ILD which is
rare in adult anti-SRP syndrome. Cardiac involvement
was noted in 2 patients with LVH on Echo [13]. All
patients had a muscle biopsy showing necrosis and in 3
cases this was with a lymphocytic infiltrate [13, 15].
Treatment schedules varied widely: All patients were
initially treated with steroids and 5/9 with methotrexate
[913–15] with a universally poor response. Three patients
showed improvement with addition of IVIG [13–15],
however 2 of these subsequently relapsed. Rituximab
was used as an induction agent in one case with a good
response [15].
Five cases were treated with cyclophosphamide: 1 case
developed ovarian failure and treatment was therefore dis-
continued [13] and 3 cases were poor responders [9, 13].
One patient had a dramatic improvement in muscle
strength with combination induction therapy using plasma
exchange and methylprednisolone followed by IV cyclo-
phosphamide and azathioprine [11, 12]. Azathioprine has
also been used successfully as a maintenance agent in com-
bination with IVIG and levflunomide following induction
with rituximab [15]. A poor response was documented in
the 2 cases where Azathioprine was used to induce remis-
sion [13, 15]. Infliximab was found to be ineffective in 3 pa-
tients [13]. Cyclosporine had a modest effect in one case
and no effect in another [13]. Tacrolimus was used in 2
patients; it was discontinued in one due to haemolytic
uraemic syndrome [13] and was ineffective in the other [9].
Mycophenalte Mofitil (MMF) was used in one patient with
a modest effect [13].
Long-term outcomes in the existing literature are vari-
able but generally poor. 3/9 patients achieved remission
and remained clinically well at the time of publication
[11, 12, 14, 15]. One of these had a period of relapse but
subsequently went back into remission [15]. Two further
cases showed initial improvement but relapsed following
an infection [9, 14, 15]. Over 50% of cases had severe
residual weakness [9, 10, 13] with 80% of that group
remaining wheelchair bound [9, 10, 13].
Discussion
Our report highlights three paediatric cases of anti-SRP
necrotising myositis presenting at a single centre during
2014–15. All 3 cases were initially identified with Immu-
noblot and subsequently confirmed by immunoprecipi-
tation. All cases were negative for other myositis specific
and myositis associated antibodies. Given the rarity of
published paediatric cases, our report helps confirm the
clinical and histological findings in the paediatric age
group and importantly, identifies an induction regime
that was effective in all 3 patients.
The original Bohan and Peter [16] criteria for IIM have
not been validated in the paediatric population and fail to
specifically identify children with necrotising myopathies.
From a clinical perspective, this distinction is essential as
patients with anti-SRP myositis fail to respond to first line
therapy for JDM and are at risk of poor outcomes.
Muscle biopsy histology alone is unlikely to accurately
distinguish necrotising myopathies from JDM, as some
cases of anti-synthetase associated myopathies can have
necrotic features, and conversely anti-SRP biopsies may
have an inflammatory infiltrate (Fig. 1, case 3). Interest-
ingly, one of our cases had tubuloreticular inclusion
bodies on electron microscopy – previously considered a
characteristic feature of DM/JDM. All our patients were
tested for anti-HMGCR by ELISA with no positive
results [17]. To ensure the correct diagnosis of anti-SRP
myositis, we would recommend that all patients diag-
nosed with Juvenile IIM be tested for MSAs including
anti-SRP.
In all 3 of our patients, standard treatment with
methotrexate and steroids failed to significantly improve
muscle strength. Each patient subsequently responded to
combination therapy with rituximab, cyclophosphamide
and IVIG, together with a longer duration of intensive
daily physical therapy. Although 2 of the more severe
cases took between 6 (case 1) and 12 (case 3) months to
regain MMT > 70 all 3 were able to regain independent
mobility. Recent data from the RIM study suggests that
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the median time to achieve a 20% improvement in
MMT8 with rituximab is 20 weeks [18]. The nature of
our report precludes definitive conclusions on the com-
parison of combination therapy vs individual agents,
however, it is notable that in all 3 of our cases an
improvement in MMT8 occurred between 12 and
16 weeks, which is earlier than data for rituximab alone.
Given that anti-SRP myositis is usually more resistant to
therapy than other forms of adult and juvenile myositis,
we suggest that our patient’s results reflect the combin-
ation of rituximab together with cyclophosphamide and
IVIG rather than from one agent alone.
Currently there is a lack of data regarding long term out-
comes of anti-SRP myositis. A recent large cohort study of
37 adult patients with anti-SRP myositis found that only
50% of their cohort reached near-full or full strength after
4 years of treatment and that most continued to have
persistently elevated CK levels [19]. This study also docu-
mented worse outcomes in their younger patients.
In spite of the good initial response to combination
therapy, two of our patients (case 1 and 2) had rising CK
levels 7–8 months after presentation, once the prednis-
olone dose had fallen below 10 mg and they remained
on MTX and IVIG alone. In both patients CK levels
responded to an escalation in corticosteroids and re-dos-
ing with rituximab. Long term follow-up of paediatric
patients is needed to monitor for evidence of ongoing
active disease after treatment.
Conclusion
This paper supports the evolving hypothesis that Anti-
SRP is clinically and histopathologically distinct from
other JIIM. It is an important differential to JDM and
should be considered where there is severe weakness
with minimal rash or in patients with highly elevated
muscle enzymes (CK > 10,000iu/l).
The current literature suggests that patients with anti-
SRP antibodies do not respond to conventional first line
therapies and have generally poor outcomes. We believe
early identification is essential so as not to delay aggressive
medical and physical therapy. Currently there is no con-
sensus on the best therapeutic protocol for these children
but our cases demonstrate that aggressive treatment with
cyclophosphamide, rituximab and IVIG, in addition to
standard therapy with methotrexate and corticosteroids
can induce remission. We advocate for intensive physio-
therapy as an integral therapeutic measure.
Adult data has shown that anti-SRP myositis is a
chronic condition with ongoing high CK levels even in
successfully treated patients [19]. More data is required
to understand if this is also true of children.
Greater international collaboration and long-term
follow-up data is needed to establish the most effective
treatment strategy for this rare group of patients.
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